Roche wins FDA approval for immunotherapy cocktail against lung cancer

Roche's Tecentriq immunotherapy mixed with chemotherapy won U.S. approval as an initial treatment for a form of lung cancer as the Swiss drugmaker seeks to establish its alternative to drugs from Merck and Bristol-Myers Squibb.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news

Related Links:

Purpose of review Recently, the combination of antiangiogenic agents, chemotherapy and immunotherapy has shown synergistic anticancer effects in non-small cell lung cancer (NSCLC). The future for this approach appears bright in lung cancer treatment; however, many challenges remain to be overcome regarding its true potential, optimal sequence and timing of therapy, and safety profile. In this review, we will discuss the current status and future direction of antiangiogenic therapy for the treatment of NSCLC, and highlight emerging strategies, such as tumor vessel normalization (TVN). Recent findings Bevacizumab was th...
Source: Current Opinion in Oncology - Category: Cancer & Oncology Tags: LUNG AND MEDIASTINUM: Edited by Robert Pirker Source Type: research
Purpose of review Controversy exists regarding the optimal treatment of patients with stage IIIA-N2 nonsmall cell lung cancer because of its heterogeneity. Patients are at risk for both local and distant disease relapse after primary local treatment. However, there may be a window of opportunity for surgery, if mediastinal downstaging has been obtained after induction therapy. This manuscript reviews the outcome of patients treated by neo-adjuvant chemotherapy (NA-C) followed by surgery, compared with patients treated with either definitive sequential or concurrent chemoradiotherapy (cCRT), illustrated by a single-centre...
Source: Current Opinion in Oncology - Category: Cancer & Oncology Tags: LUNG AND MEDIASTINUM: Edited by Robert Pirker Source Type: research
A new radiomics technique can determine which lung cancer patients will benefit...Read more on AuntMinnie.comRelated Reading: AI, radiomics predict prostate cancer aggressiveness CT radiomics uses immunohistology to detect thyroid cancer AI can improve reproducibility of radiomics in CT Can radiomics detect pancreatic ductal adenocarcinoma? AI, radiomics can help predict chemotherapy response
Source: AuntMinnie.com Headlines - Category: Radiology Source Type: news
In conclusion, solid data regarding the benefit of ICIs in ECOG PS2 NSCLC patients are currently lacking and the role of immunotherapy remains uncertain for PS2 patients. Prospective randomized trials addressing this question are warranted or ongoing. However, we are concerned that without a more extensive and objective assessment of patients ’ fitness and frailty by using and validating appropriate tools a clear answer may not come to light.
Source: Current Oncology Reports - Category: Cancer & Oncology Source Type: research
In conclusion, our study delineate a new mechanism used by lung cancer cells to inhibit NK cell’s anti-cancer activity through exosome delivery, and inspire further research into the clinical application of miR-150 inhibition for immunotherapy.
Source: European Respiratory Journal - Category: Respiratory Medicine Authors: Tags: Molecular pathology and funct. genomics Source Type: research
Conclusions: In our hospital, molecular diagnostic is performed in all patients with advanced NSCLC to customize therapy. This study, while showing our local experience, corroborates data obtained in the literature. Thus, despite the small sample size, this may be the basis for future studies and help improve clinical practice.
Source: European Respiratory Journal - Category: Respiratory Medicine Authors: Tags: Lung cancer Source Type: research
Conclusion: Bronchoscopic re-biopsy for progressive lung cancer is feasible and safe. Histological change can be detected in a considerable number of patients, which is potentially valuable information for guidance of subsequent treatment.
Source: European Respiratory Journal - Category: Respiratory Medicine Authors: Tags: Lung cancer Source Type: research
Objective: Anti-PD-1 antibodies can cause drug-induced pneumonitis. We aimed to identify the clinical and radiologic characteristics, the incidence, risk factors, and appropriate management of pneumonitis related to anti-PD-1 immunotherapy in patients with non-small cell lung cancer (NSCLC).Materials and Methods: Medical records and chest computed tomography scans of patients with NSCLC treated with anti-PD-1 antibodies between January 2016 and June 2018 at the Kanagawa Cancer Center were retrospectively analyzed. Clinical characteristics of patients treated with anti-PD-1 antibodies who developed pneumonitis were compared...
Source: European Respiratory Journal - Category: Respiratory Medicine Authors: Tags: Lung cancer Source Type: research
Conclusions: In this study we confirmed that ICI drugs can occasionally develop clearly defined autoimmune systemic diseases besides pulmonary toxicity. While discontinuation of therapy and/or treatment can result in resolution of irAEs, long-term sequelae and death have been reported. More studies are needed in order to develop more precise treatments for immunotherapy-related adverse events.
Source: European Respiratory Journal - Category: Respiratory Medicine Authors: Tags: Lung cancer Source Type: research
ConclusionThe confinement within the radiation field and the latency of appearance are suggestive of delayed radiation myelopathy. Nevertheless, the relatively low dose of radiation received and the full recovery after pembrolizumab discontinuation and steroid therapy plead for the contribution of both radiotherapy and immunotherapy in the causality of this complication, as an enhanced inflammatory reaction on a focal post-radiation chronic inflammatory state. In the three previously described cases of myelopathy occurring after radiotherapy and immunotherapy, a complete recovery had not been obtained and the immunotherapy...
Source: Journal for Immunotherapy of Cancer - Category: Cancer & Oncology Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | Health | Immunotherapy | Lung Cancer | Merck | Switzerland Health